Internationalisation | inXso https://inxso.pro We bridge the gap between medical research, the development of medical innovation, and international commercialization Thu, 10 Apr 2025 08:18:55 +0000 en-US hourly 1 https://wordpress.org/?v=6.8.1 Empowering Innovation within EIC Partnership Ecosystem https://inxso.pro/insights/empowering-innovation-within-eic-partnership-ecosystem/ Mon, 07 Apr 2025 05:00:00 +0000 https://inxso.pro/?p=249921

After the EIC Summit 2025 and EIC Partners Day, it is a good time to reflect on the past year of ecosystem partnership with the European Innovation Council (EIC) for internationalisation. Looking back to 2023, when EIC decided to expand their EIC service catalogue with a new section focusing on internationalisation, inXso had the pleasure of joining as one of the first and few to focus exclusively on the healthcare sector.

Dedicated Programmes for EIC Beneficiaries

Supporting EIC Awardees and Seal of Excellence holders in their internationalisation efforts has been just a tiny part of the ever-evolving collaboration with the EIC, as the programme presents an exceptional platform to exchange insights and expertise within the ecosystem with some of the best innovators in Europe.

The extent of on-demand services provided by the EIC ecosystem is illustrated by initiatives such as the Tech2Market Venture Building programme, which focuses on leveraging research results to build ventures from viable business ideas, and the EIC Access+ call, created exclusively to accelerate Deep-Tech Innovations.

Within such programmes, inXso is dedicated on supporting EIC pathfinder, EIC transition, EIC accelerator, and EIC Seal of Excellence holders in realising their innovation paths and developing their businesses to be market-access ready in the highly regulated healthcare sector.

EIC beneficiaries have developed their R&D roadmaps and successfully navigated regulatory challenges while building sustainable financial models, all by utilising our unique interdisciplinary and international expertise

Backing Visionary Entrepreneurs

Since inXso is providing specific niche support focusing on the on-demand needs of the EIC beneficiary, the support may include grassroots essentials such as compiling technical documentation, ensuring ISO 13485:2016 compliance, designing clinical trials according to ISO 14155:2020, creating risk management plans according to ISO 14971:2019, and IEC 62366 ensuring usability in the process, to name a few.

On a higher level, EIC beneficiaries have ensured their investor readiness by creating additional assets through inXso’s technical assessment, building sustainable financial models and fundraising strategies through inXso’s business development insights, and developing regulatory roadmaps with viable reimbursement models to access international markets leveraging inXso’s international regulatory expertise.

Learning from the Best

Since emerging medical technologies are the cornerstone of inXso’s activities in our continuous and ever-evolving cooperation with research teams, helping EIC beneficiaries is one of the areas where we feel most comfortable.

At the same time, it has been a great pleasure to see and get to know the cream of the crop of innovations supported by the EIC ecosystem and to learn from the latest research.

Given the nature of emerging medical technologies, it is not a straightforward process to establish regulatory routes as, in many cases, the current regulatory framework does not cover the innovation – yet, since regulatory compliance is reactive in nature and evolves according to the latest research seeking its way to market.

However, precisely because of these challenges, nothing is as rewarding as seeing cutting-edge research reach healthcare providers and patients.

About inXso

Born internationally, we help innovators open new lines of research and technology that are disrupting existing healthcare ecosystems.

inXso is an innovation agency specialising in breakthrough, disruptive, and emerging technologies for healthcare, covering deep tech and nanotechnology solutions for medical, biomedical, and health technology. Following our motto, “We bridge the gap between medical research, the development of medical innovation, and international commercialisation”, we provide expertise in co-innovation and development, international business development, and innovation procurement support.

inXso provides services in the healthcare sector with three focus areas:

EIC Partner for Internationalisation

Get familiar with our support for internationalisation in the healthcare sector in the EIC Catalogue.

The post Empowering Innovation within EIC Partnership Ecosystem first appeared on inXso.

]]>
Internationalisation Services for EIC Beneficiaries in the Healthcare Sector https://inxso.pro/insights/internationalisation-services-for-eic-beneficiaries-in-the-healthcare-sector/ Mon, 08 Jan 2024 04:00:00 +0000 https://inxso.pro/?p=248435 Internationalisation services for EIC beneficiaries in the healthcare sector are provided by inXso in the framework of the EIC Ecosystem Partnership.

The post Internationalisation Services for EIC Beneficiaries in the Healthcare Sector first appeared on inXso.

]]>

EIC Internationalisation Services by inXso

Internationalisation services for EIC beneficiaries in the healthcare sector are provided by inXso in the framework of the EIC Ecosystem Partnerships and Co-Investment Support programme.

Due to the extensive network of experts operating in this area, the internationalisation services are focused profoundly on internationalisation in the US, the United Arab Emirates (UAE) and Asia, in particular Japan, South Korea, Malesia and Taiwan.

Tailored to meet the needs of EIC beneficiaries from the Health and medical care, Biotechnology and Health Tech, and Pharmaceuticals sectors, specifically such as:

  • Medical Devices
  • Implantable devices
  • Digital Health
  • Biopharmaceuticals, Biosimilars
  • Cell & Gene Therapeutics
  • Tissue Engineered Medicines
  • Cell-based Medicines
  • Combined ATMPs
  • Integrated Drug Delivery Devices
  • AI Integrated solutions

The service is directed to EIC pathfinder, EIC transition and EIC accelerator innovators in all TRL levels, henceforth beneficial to EIC beneficiaries in the research stage, spinout/startup, and scale-up.

inXso is partnering up with the European Innovation Council (EIC)

We’re delighted to share that inXso is now a new member of the European Innovation Council (EIC) network of organizations offering a set of EIC internationalisation services, aligning us with a vibrant community dedicated to supporting over 6,000+ innovations across Europe.

The Significance of Internationalisation Services

Companies in the healthcare sector are facing a solid push towards internationalisation in order to recover their investment and increase turnover as they operate in a particular niche market sector with a very limited domestic market.

At the same time, the companies are faced with forces constraining operations, as the industry involving implementation of medical research to improve health care and quality of life distinguishes itself from other high-technology sectors in that it has precise requirements when it comes to standardisation, quality management and regulatory compliance.

Emerging, breakthrough, and deep health technologies have a competitive edge much needed in accessing the health market, yet they may need more design aspects for overseas adaptation.

Concurrently, healthcare is inherently local with culture and nation-specific requirements to meet the safety design of the technology. Moreover, the purchasing decisions involve the need to understand how reimbursement works within the healthcare ecosystem.

inXso’s internationalisation services for EIC beneficiaries are tailored to address these barriers and accelerate market access from the HealthTech, MedTech, BioMedTech and Biotech & Pharma sectors.

EIC Internationalisation services

Assessment of the Asian, the US and the UAE Markets for the Healthcare Sector

Build capacity for agile internationalisation through co-creation and co-design via individual training and coaching tailored to the needs of biomedical technology, medical technology, biotech and pharma industry.

The assessment will map the development process, considering its current TRL level and the value chain, including customers, competitors, public authorities, and other stakeholders relevant to the innovation’s development, approval, adaptation, and implementation.

Key features:

  • Market-specific trends and business opportunities.
  • Assessment of technological, market, financial, and clinical feasibility aspects.
  • Market-specific requirements for the development and market access stage.

Benefits for EIC beneficiaries in i) research stage, ii) spinout/startup, iii) scale-up:

  • Accelerate the R&D process by ensuring that the product meets multinational customers’ needs, processes and environment.
  • Gain an understanding of how to adapt the product for multinational markets and implement the adaptation agilely in healthcare units, biomedical facilities or clinical environments.
  • Gain an understanding of where the innovation may have the most need, its safety, efficacy, and cost-effectiveness in its user environment that, in turn, will give a competitive edge and marketing advantage.

The aim is to accelerate the innovation development process from its current TRL to market, create an agile approach and provide expertise to build a value chain that fits the ecosystem.

The service is directed to EIC pathfinder, EIC transition and EIC accelerator innovators by dedicated in-house or external experts depending on the target market via online, offline or hybrid models.

Learn more

Assessment of the Asian, the US and thr UAE markets for Healthcare Sector – The service is directed to EIC beneficiaries from the HealthTech, MedTech, BioMedTech and Biotech & Pharma sectors.

International Business Design Focused on Asia, the US, and the UAE

Build capacity for agile market entry and expansion through co-creation and co-design via individual training and coaching tailored to the needs of biomedical technology, medical technology, biotech, and pharma industry.

Considering its current TRL level and value chain, the guidance will navigate through innovative business models, commercialisation, Go2Market, and reimbursement strategies.

Key features:

  • Business model optimisation with review & analysis.
  • Business strategy optimisation with review & analysis.
  • Commercialisation strategy optimisation with review & analysis.
  • Regulatory gap analysis and reimbursement strategy.
  • Market entry strategy analysis.
  • Growth hacking.
  • Distribution channels with cost estimation analysis.
  • Strategic partnerships & agreement negotiation.

Benefits for EIC beneficiaries in i) research stage, ii) spinout/startup, iii) scale-up:

  • Ensure your local market fit: Align policies with the local legislation and business practices.
  • Secure revenues and stay ahead of competitors: Incorporate a feasible reimbursement strategy according to the local legislation.
  • Accelerate market entry: Understand how the local health ecosystem works and align the go2market strategies accordingly.
  • Clinical evaluations: Prepare in advance in case they are required for market accession. Also, use them in assessing the pricing model.
  • Product success: Ensure reimbursement strategies optimally meet the target market regulatory requirement.

The service is directed to EIC pathfinder, EIC transition, and EIC accelerator innovators by dedicated in-house or external experts depending on the target market via online, offline, or hybrid models.

Learn more

International Business Design focused on Asia, the US and the UAE – The service is directed to EIC beneficiaries from the HealthTech, MedTech, BioMedTech and Biotech & Pharma sectors.

R&D Support for International Commercialisation for Healthcare Sector

Build capacity for inherent safe-by-design, standardisation, quality, and regulatory assurance through co-creation and co-design via individual training and coaching tailored to the needs of biomedical technology, medical technology, biotech, and the pharma industry.

The guidance will navigate the framework for complex health and medical care technologies, especially borderline cases, customised and personalised solutions that are challenging due to regulatory barriers, considering its current TRL level and the value chain.

Key features:

  • Design of Experiments (DoE) and Human Factors Engineering (HFE)
  • Proof of Concept (PoC) and prototyping.
  • Safe-by-Design, and cross-cultural and cross-national design.
  • Standardisation, Risk Management and QARA.
  • Verification and Validation.
  • Clinical design.

Benefits for EIC beneficiaries in i) research stage, ii) spinout/startup, iii) scale-up:

  • Demonstrate the viability by early end-user feedback and check the manufacturability, cost, acceptability, accessibility, and market relevance of the final design.
  • Incorporate requirements of the intended or potential market areas in the research and development phase, avoid costly redesign phases, and increase user safety of the innovation by considering multicultural design features.
  • Incorporate target market-specific design features and carry out clinical evaluations to ensure regulatory compliance.

The aim is to accelerate innovations for health and medical care with high quality that are ready for the regulatory approval process and user-safe.

The service is directed to EIC pathfinder, EIC transition, and EIC accelerator innovators by dedicated in-house or external experts depending on the target market via online, offline, or hybrid models.

Learn more

R&D Support for International Commercialisation for Healthcare Sector – The service is directed to EIC beneficiaries from the HealthTech, MedTech, BioMedTech and Biotech & Pharma sectors.

What is the EIC Ecosystem Partnerships and Co-Investment Support Programme?

The EIC Partners are selected under the EIC Ecosystem Partnerships and Co-Investment Support programme.

Launched in 2021, this programme has the goal of expanding the EIC Business Acceleration Services by addressing two of the greatest challenges for its innovators: access to specialised sector-focused services and attracting private investors.

The EIC Partners address the first need by providing:

  • Standalone services such as workshops, training and matchmaking on topics that aren’t covered by BAS.
  • Highly specific, niche services, such as the usage of specific laboratory equipment or technological due-diligence, and even relocation services and IPO coaching.
  • Integration into partner’s accelerations, incubation, or venture building programmes, according to the technology stage and specificities of the innovators’ project.

On the co-investment front, beneficiaries are supported and trained to make the most of their interactions with investors and matched with the most relevant ones, both through events and direct introductions.
For more information, please refer to the EIC Ecosystem Partnerships and CoInvestment Support programme webpage.

About European Innovation Council

The European Innovation Council (EIC) has been established under Horizon Europe, with a budget of over €10 billion (2021-2027) to support game-changing innovations throughout their lifecycle, from early-stage research to market.

The EIC provides funding opportunities for companies in different stages of technological maturity through its instruments: EIC Pathfinder, EIC Transition and EIC Accelerator. These projects are selected through highly rigorous and competitive processes.

EIC Accelerator projects can receive up to €2.5M in grant funding, and are further eligible for up to €15M in direct equity investments from the EIC Fund. EIC innovators are also given access to the EIC Business Acceleration Services (BAS), which include coaching, mentoring and opportunities with corporates, procurers and investors.

The post Internationalisation Services for EIC Beneficiaries in the Healthcare Sector first appeared on inXso.

]]>
New Partnership Goals: inXso and BrainStormCorner https://inxso.pro/insights/new-partnership-goals-inxso-and-brainstormcorner/ Tue, 18 Oct 2022 05:00:00 +0000 https://inxso.pro/?p=247153 inXso is glad to share our new partnership goals with BrainStormCorner, founded as a business think tank with global roots, born right next to Tampere University campus. BrainStormCorner is a versatile toolbox of business services and research commercialization, based on long international and multidisciplinary experience.

The post New Partnership Goals: inXso and BrainStormCorner first appeared on inXso.

]]>

inXso is glad to share our new partnership goals with BrainStormCorner, founded as a business think tank with global roots, born right next to Tampere University campus. BrainStormCorner is a versatile toolbox of business services and research commercialization, based on long international and multidisciplinary experience.

“While Finnish, we are extremely multilingual.”

With our common goals, inXso and BrainStormCorner will strive forwards to provide valuable insights for co-innovative solutions and international business development through upcoming collaboration offerings.

What to look forward to?

Through the partnership, both inXso and BrainStormCorner can provide a unique and in-depth insight into the international development of technology companies. We provide a platform for Finnish and foreign companies and start-ups. We help you to take the right steps towards building your business in Finland, or to develop your offering and expand abroad.

Our clients benefit from our multidisciplinary understanding of different technologies, as we speak both business and technology. We have long-standing international business insight in East Asia and Europe, which allows our clients to overcome barriers to market entry, identify business opportunities and provide practical solutions tailored to their needs.

Outstanding services currently available:

Companies and startups receive support for ideation, facilitation, engagement, project planning and hands-on experience for:

For very early stage entrepreneurs:

This support system is available for very early stage entrepreneurs in Tampere region. There are no restrictions for the company’s field of activity. Tailored, intensive and valuable business development packages are available for those individuals who send an application and are accepted into the program: Pirkanmaan Yrittäjyysbuusti, Pirkanmaa Entrepreneurial Boost – BrainStormCorner 

Learn more at BrainStormCorner

About inXso

Born internationally, we are helping innovators open up new lines of research and technology that are disrupting existing healthcare ecosystems.

inXso provides services in the healthcare sector with three focus areas:

The post New Partnership Goals: inXso and BrainStormCorner first appeared on inXso.

]]>
How to Build Internationalisation Strategy for HealthTech https://inxso.pro/insights/how-to-build-internationalisation-strategy-for-healthtech/ Mon, 19 Oct 2020 03:00:00 +0000 https://inxso.pro/?p=649 An internationalisation strategy for healthcare technology faces a multitude of specific considerations due to its operation in a heavily regulated environment.

The post How to Build Internationalisation Strategy for HealthTech first appeared on inXso.

]]>

Internationalisation Starts with a Strategy

Internationalisation attempts usually fail due to a lack of thorough preparation and adherence to the chosen internationalisation strategy.

When it comes to the medical industry—such as life sciences, healthcare technology, biomedical technology, and pharmaceuticals—which operates in a heavily regulated environment, any attempt to seek market growth through internationalisation faces a multitude of specific considerations.

The most crucial step is ensuring international standardisation and regulatory requirements, which are at the core of innovation design when strategising for global market access for the medical industry. When done right, aligning regulatory strategy for many target countries is advantageous, especially for nìche medical products, which should not be overlooked at the R&D phase.
However, when analysing the potential market, one essential aspect is understanding the local healthcare ecosystem and its advantages and disadvantages compared to the domestic market, often used for innovation validation.

In an ideal case, internationalisation has been integrated into the R&D process because the target market may encompass cross-cultural and cross-national aspects that need consideration in the design phase. Cross-cultural and cross-national elements are critical for the safe-by-design process, defined by international Human Factors and Usability Engineering and Risk Management standards. The safe-by-design process requires the earliest possible identification of target countries, enabling the implementation of regulatory requirements into the R&D process by aligning them where applicable.

In most cases, companies opt for a localisation approach that seems a more robust solution but could cause some design alterations specific to the target market afterwards.

Whether the strategy is to build a global design targeting many countries simultaneously or localisation where domestic design is localised target country-specific, it is crucial to know, understand, and research the target market when expanding to another country.

Once it is clear that the device, application, or product fits into the target market, it is time to assess if there is a demand for it and how attractive the market is considering the competition.

Legislations do Differ

Every country has its laws and regulations that must be adhered to, and preparing for the regulatory requirements is a must, and it is best done with someone who understands the local legislation and business environment. To highlight a few essential stumbling blocks in the regulatory framework most startups in the medical industry face once they seek growth internationally.

For some companies, it may come as a surprise that standards for quality management systems are not necessarily harmonised and that national guidelines apply in significant healthcare markets. The classification of medical devices differs as well; a medical product that might be classified as an in vitro diagnostic device in the EU could be a class I medical device in a non-EU country, for example. The need for clinical trials is quite specific, depending on the local legislation and applicable regulatory pathway(s). For reimbursement strategy, it is essential to understand how the local healthcare system works: 

  • How much is healthcare spending, and what is the role of the government and insurance companies? 
  • How much is paid by the government, and how much is covered by the insurance? 
  • How much is the compulsory insurance, and how much is paid out-of-pocket by the patient? 
  • Who decides on the treatment? The physicians or the insurance company who pays the bill? 

The reimbursement landscape is usually deemed complicated due to the fragmented healthcare system and medical device distribution, including invoicing.

The one thing that most companies need to pay more attention to is the IP protection strategy, which requires thorough planning with the local legal system in mind.

Business Models and Partnerships

When considering appropriate market entry strategies, adapting the business model to the environment is an iterative process where market fit, distribution, and partnerships are some of the factors to consider. Also, what skills and resources are needed for successful business operations, and is there a need to relocate workers or hire locally in critical positions? Modifying the business model may take considerable time as it involves many managerial questions, including R&D and Know-How against IPR infringements.

“Appropriate partnerships are the key” to successful internationalisation, and it will also influence the business model, so taking time to research the critical players thoroughly will pay back subsequently when creating a supply chain management system. One of the most essential aspects of partnerships concerns distributors, with whom discussions also need considerable attention regarding the trust of business operations. It is worth noting that all of this will influence the import and export operations in terms of manufacturing and financial issues.

Although building an appropriate action plan for the internationalisation of healthcare technology depends on the device, application, or product as well as the target market, this outlines those aspects essential for building an effective internationalisation strategy.

Even if not all of the above applies to a specific case, they should be considered when drafting plans.

Essential factors to consider when drafting an internationalization strategy for healthtech.

Behind Successful Internationalisation Strategy

Building a successful, target-oriented internationalisation strategy for healthcare technology requires understanding the local ecosystem and exceptionally comprehensive preparation.

Behind every successful international expansion of healthcare companies lies an incredible amount of thorough groundwork for market analysis, as well as for the regulatory and reimbursement landscape.

A sustainable financial strategy is essential for market entry, and it will include aspects such as partnerships and supply chain options, as well as the team’s core competencies.

The post How to Build Internationalisation Strategy for HealthTech first appeared on inXso.

]]>
The Internationalisation Challenge of Biomedical Innovations https://inxso.pro/insights/the-internationalization-challenge-of-biomedical-innovations/ Mon, 15 Jun 2020 03:00:00 +0000 https://inxso.pro/?p=486 Bringing biomedical innovations to healthcare and patient care globally requires careful consideration of technical, legal, and ethical requirements.

The post The Internationalisation Challenge of Biomedical Innovations first appeared on inXso.

]]>

Table of Contents

Intro: Biomedical Innovations

Biomedical Innovations Among High-Technology Industries

Forces Enabling and Constraining Internationalization

Decrease the Barriers to Internationalization

Diagram: Outline of Biomedical Innovation R&D

Technologies in biomedical innovations unite life sciences, medical sciences, data sciences, and physical sciences and aim to improve the understanding of diseases and how to diagnose and treat them.

Some examples of biomedical innovations include:

  • Prosthetics
  • Medical imaging solutions
  • Implantable medical and drug delivery devices
  • Robotic and laser instruments to assist in surgeries
  • Nanomaterials
  • Bioprinting
  • Genome editing

Some examples of the evolving trends in biomedical innovations include:

  • Personalised medicine
  • Medical virtual reality
  • Artificial intelligence in medical imaging
  • Wearable medical devices
  • Surgical robotics
  • Nanorobots
  • organs-on-chips

Bringing such innovations to healthcare and patient care on a global scale entails an immense amount of technical, legal and ethical considerations and requirements. Also known as the internationlisation challenge of biomedical innovations. 

Biomedical Innovations Among High-Technology Industries

The industry involving biomedical innovations distinguishes itself from other high-technology industries with such fundamental dimensions as applying scientific knowledge to provide technological solutions aiming to improve health care and quality of life – in a highly regulated environment. At the same time, purchasing decisions are usually not made by end-consumers but by their physicians or such third parties as an insurance company, for example.

Early internationalisation is facilitated by simultaneous forces, both empowering and constraining operations: To recover their investments and to increase turnover, biomedical technology companies, especially, are facing a solid push towards an international outlook with high technology that has a competitive advantage at an early stage but is not culture-specific.

The first challenge that early-stage companies in the medical industry face is the need for more understanding of how the healthcare ecosystem works globally, including how to meet inherent safety design features, quality management and standardisation requirements of the diverse target markets and navigate the complex regulatory landscape.

However, finding appropriate partners is a critical challenge in internationalisation and often depends on the right network.

Forces Enabling and Constraining Internationalisation

In principle, unchanged biomedical technologies are usually introduced into international markets because manufacturers must comply with local regulations in the manufacturer’s country and assume that users will adapt to the new technology through training.

However, training is often ineffective when faced with ingrained customs and user expectations in individual countries, which can be seen during the transition phase in the increased use error rate when operating new technology.

As mentioned, the biomedical industry is highly regulated, so companies must comply with local demands in their international business activities. Logically, adhering to compliance with a single country’s requirements can result in a design likely to induce use errors in another country with different user needs and expectations or use-shaping factors.

Hence, device features should be designed cross-cultural and cross-national requirements in mind, especially as failure to meet these requirements could easily violate the international risk management (ISO 14971) and usability (IEC 62366) standard compliance.

Reimbursement strategy is another factor that most companies do not plan early enough when planning internationalisation; “Who pays for your product?” is a very relevant question as it dictates who will be financing the healthcare industry across nations. For example, in the Nordics, healthcare is mainly funded through the social security system, whereas in the US and Germany – example-wise – health insurance is the most preferred financial model.

Nonetheless, a solid push exists to expand from smaller home markets across borders due to the need to amortise high research and development (R&D) costs. Even when most companies have limited financial and managerial resources, the key challenge identified by many biomedical companies operating in an international healthcare market is to find appropriate partners for ventures.

Apart from complying with regulatory demands and financing the R&D process, organising clinical trials, including difficulties in getting access to hospitals and doctors, as well as scaling up marketing and sales, are among the challenges making an international product launch a complex endeavour.

Decrease the Barriers to Internationalisation

Companies developing biomedical innovations should prepare early on to overcome barriers in local and international markets and demonstrate credible and robust implementation measures to secure the necessary funding.

It is essential to invest in building teams of experienced medical technology, regulatory and quality control specialists to ensure the quality of the product and market access in an agile way.

It is advisable to seek input from stakeholders outside of the local ecosystem to avoid the “echo chamber” and to understand the unique added value that innovation brings to healthcare.

Biomedical innovations are challenging to internationalise.

Diagram: Outline of Biomedical Innovation R&D. Non-exhaustive “mindmap” of the R&D project for Biomedical Innovation, which also constrains the internationalisation process.

The post The Internationalisation Challenge of Biomedical Innovations first appeared on inXso.

]]>
What are the Key Points of Chinese Health Tech Initiatives – Join Discussion on May 29th https://inxso.pro/insights/what-are-the-key-points-of-chinese-health-tech-initiatives-join-discussion-on-may-29th/ Mon, 13 Apr 2020 03:00:00 +0000 https://inxso.pro/?p=1465 inXso is organizing an interactive webinar to discuss some key points and unique aspects of Chinese Health Tech initiatives and their implementation.

The post What are the Key Points of Chinese Health Tech Initiatives – Join Discussion on May 29th first appeared on inXso.

]]>

What are we Discussing?

In our series focusing on Health Tech in the Chinese market, inXso is organizing an interactive webinar, “What are the Key Points of Chinese Health Tech Initiatives—Join Discussion on May 29th,” together with Tampere HealthHUB.

The webinar will briefly discuss some of the key points and unique aspects of Chinese Health Tech initiatives and their implementation.

We will examine the concept of “Big Data” and its role in Health Tech development, market research, and marketing from a Chinese point of view. We will also provide an overview of the regulatory and IP landscape in China that European Health Tech companies should be aware of before entering the Chinese markets.

As a hierarchical society, China has its own perspectives on the R&D management structure that will influence decision-making and communication. We will see the advantages and disadvantages that this might bring to collaboration with Western companies.

    When: May 29th 2020

    Where: Online

    Registration: Create your profile by May 27th 2020 by following the registration link.

    We have created a Health Tech China Focus channel that will allow all participants to engage in the discussion.

    We wish to make this an interactive discussion rather than just an informative webinar so participants may share their comments and questions in the chat room.

    Welcome to join us!

    The post What are the Key Points of Chinese Health Tech Initiatives – Join Discussion on May 29th first appeared on inXso.

    ]]>